ONTOLOGY REPORT - ANNOTATIONS
| Term: | bromocriptine |
|
| Accession: | CHEBI:3181
|
browse the term
|
| Definition: | An indole alkaloid that has formula C32H40BrN5O5. |
| Synonyms: | exact_synonym: | (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman |
| | related_synonym: | (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman; (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione; (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman; 2-bromo-alpha-ergocryptine; 2-bromo-alpha-ergokryptin; 2-bromo-alpha-ergokryptine; C32H40BrN5O5; InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1; InChIKey=OZVBMTJYIDMWIL-AYFBDAFISA-N; [H][C@@]12Cc3c(Br)[nH]c4cccc(C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N5CCC[C@@]25[H])C1=O)C(C)C)c34; bromocriptinum; bromocryptine; bromoergocriptine |
| | xref_casrn: | 25614-03-3 |
| | xref: | Beilstein:741357 "Beilstein Registry Number"; ChEMBL:107065 "ChEMBL COMPOUND"; ChemIDplus:25614-03-3 "CAS Registry Number"; DrugBank:DB01200 "DrugBank"; KEGG COMPOUND:25614-03-3 "CAS Registry Number"; KEGG COMPOUND:C06856 "KEGG COMPOUND"; KEGG DRUG:D03165 "KEGG DRUG" |
| | xref_mesh: | MESH:D001971 |
| | xref: | Patent:DE1926045 "Patent"; Patent:US3752814 "Patent"; Wikipedia:Bromocriptine "Wikipedia" |
|
|
bromocriptine
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
increases activity |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
increases expression |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
multiple interactions |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
increases expression |
EXP |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
multiple interactions |
EXP |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Atf3 |
activating transcription factor 3 |
|
increases expression |
ISO |
13 |
107,191,622 |
107,223,850 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
decreases secretion |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
multiple interactions |
ISO |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
|
decreases expression |
EXP |
8 |
61,793,976 |
61,805,308 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects binding |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Dbh |
dopamine beta-hydroxylase (dopamine beta-monooxygenase) |
|
decreases activity |
ISO |
3 |
6,052,706 |
6,069,826 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
decreases expression |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
multiple interactions |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
multiple interactions |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
affects response to substance |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
affects expression |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
increases response to substance |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
decreases expression |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
increases expression |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
multiple interactions |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd3 |
dopamine receptor D3 |
|
multiple interactions |
EXP |
11 |
58,446,901 |
58,520,589 |
RGD:6480464 |
CTD |
| G |
Drd3 |
dopamine receptor D3 |
|
decreases expression |
EXP |
11 |
58,446,901 |
58,520,589 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
increases expression |
ISO |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Gdnf |
glial cell derived neurotrophic factor |
|
decreases expression |
ISO |
2 |
57,399,312 |
57,424,030 |
RGD:6480464 |
CTD |
| G |
Gdnf |
glial cell derived neurotrophic factor |
|
decreases secretion |
ISO |
2 |
57,399,312 |
57,424,030 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
decreases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
decreases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
decreases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
increases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
decreases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
decreases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
decreases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Gh1 |
growth hormone 1 |
|
decreases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
decreases expression |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Lhb |
luteinizing hormone beta |
|
increases expression |
ISO |
1 |
95,892,999 |
95,893,988 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
increases localization |
ISO |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
increases secretion |
ISO |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
|
multiple interactions |
EXP |
13 |
49,931,592 |
50,048,756 |
RGD:6480464 |
CTD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
multiple interactions |
EXP |
3 |
120,008,715 |
120,012,589 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
decreases expression |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
multiple interactions |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases expression |
ISO |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Prkcd |
protein kinase C, delta |
|
multiple interactions |
EXP |
16 |
5,954,218 |
5,975,743 |
RGD:6480464 |
CTD |
| G |
Prkcd |
protein kinase C, delta |
|
affects localization |
EXP |
16 |
5,954,218 |
5,975,743 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
EXP |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Scarb1 |
scavenger receptor class B, member 1 |
|
multiple interactions |
EXP |
12 |
32,390,183 |
32,457,661 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
ISO |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Star |
steroidogenic acute regulatory protein |
|
decreases expression |
EXP |
16 |
70,642,580 |
70,647,203 |
RGD:6480464 |
CTD |
| G |
Stat5a |
signal transducer and activator of transcription 5A |
|
affects localization |
ISO |
10 |
89,795,404 |
89,819,732 |
RGD:6480464 |
CTD |
| G |
Tgfa |
transforming growth factor alpha |
|
multiple interactions |
EXP |
4 |
120,355,649 |
120,437,772 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
EXP |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vip |
vasoactive intestinal peptide |
|
multiple interactions |
ISO |
1 |
36,361,513 |
36,369,594 |
RGD:6480464 |
CTD |
| G |
Vip |
vasoactive intestinal peptide |
|
multiple interactions |
EXP |
1 |
36,361,513 |
36,369,594 |
RGD:6480464 |
CTD |
Term paths to the root
|